Comparison of Repaglinide and Metformin Administered Alone or in Combination in Type 2 Diabetes

A 3-month, Open-label, Randomized, Multi-center Study of Repaglinide in Combination With Metformin as Compared to Metformin or Repaglinide Given as Monotherapy for the Treatment of Type 2 Diabetes.

This trial is conducted in Asia. The aim of this trial is to compare repaglinide and metformin administered alone or in combination in subjects with type 2 diabetes.

Inclusion Criteria:

• Previously treated with oral hypoglycaemic agents (OHA) as monotherapy (if metformin, less than 1500 mg daily)
• Body Mass Index (BMI) of 21-35 kg/m^2
• HbA1c (glycosylated haemoglobin A1c) between 7.0-10%

Exclusion Criteria:

• Treatment with insulin within the last 3 months preceding the trial
• Uncontrolled treated or untreated hypertension (systolic blood pressure above or equal to 180 mm Hg, and/or diastolic blood pressure above 105 mm Hg)
• Participation in any other clinical trial within 30 days of screening